Tenax Therapeutics annual free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Tenax Therapeutics Free Cash Flow (FCF) History (TENX)
Tenax Therapeutics reported −$11.4M in free cash flow for fiscal 2022, a decrease of $529,439 from the previous fiscal year.
View full Tenax Therapeutics company overviewTenax Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$11.4M | −$529,439 | — | — |
| 2021 | 2021-12-31 | −$10.9M | −$1.6M | — | — |
| 2020 | 2020-12-31 | −$9.3M | −$1.7M | — | — |
| 2019 | 2019-12-31 | −$7.6M | −$2.1M | — | — |
| 2018 | 2018-12-31 | −$5.5M | $6.6M | — | — |
| 2017 | 2017-12-31 | −$12.1M | $3.7M | — | — |
| 2016 | 2016-12-31 | −$15.9M | −$6.1M | — | — |
| 2015 | 2015-04-30 | −$9.8M | −$481,653 | — | −19788.64% |
| 2014 | 2014-04-30 | −$9.3M | −$4.3M | — | −5833.77% |
| 2013 | 2013-04-30 | −$4.9M | $3.4M | — | −414.68% |
| 2012 | 2012-04-30 | −$8.3M | $347,948 | — | −2280.50% |
| 2011 | 2011-04-30 | −$8.6M | — | — | −8378.62% |
Tenax Therapeutics quarterly free cash flow
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q1.16
Q1.16
Q1.16
Q2.16
Q2.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2023 | 2023-06-30 | −$924,568 | $2.5M | — | — |
| Q1 2023 | 2023-03-31 | −$1.7M | $1.2M | — | — |
| Q4 2022 | 2022-12-31 | −$1.7M | $1.1M | — | — |
| Q3 2022 | 2022-09-30 | −$3.3M | −$307,717 | — | — |
| Q2 2022 | 2022-06-30 | −$3.4M | −$1.6M | — | — |
| Q1 2022 | 2022-03-31 | −$2.9M | $277,141 | — | — |
| Q4 2021 | 2021-12-31 | −$2.8M | −$779,217 | — | — |
| Q3 2021 | 2021-09-30 | −$3.0M | −$637,743 | — | — |
| Q2 2021 | 2021-06-30 | −$1.8M | $381,963 | — | — |
| Q1 2021 | 2021-03-31 | −$3.2M | −$550,112 | — | — |
| Q4 2020 | 2020-12-31 | −$2.0M | −$264,679 | — | — |
| Q3 2020 | 2020-09-30 | −$2.4M | −$603,105 | — | — |
| Q2 2020 | 2020-06-30 | −$2.2M | −$314,167 | — | — |
| Q1 2020 | 2020-03-31 | −$2.7M | −$534,644 | — | — |
| Q4 2019 | 2019-12-31 | −$1.7M | −$526,828 | — | — |
| Q3 2019 | 2019-09-30 | −$1.8M | −$226,645 | — | — |
| Q2 2019 | 2019-06-30 | −$1.9M | −$724,407 | — | — |
| Q1 2019 | 2019-03-31 | −$2.1M | −$574,815 | — | — |
| Q4 2018 | 2018-12-31 | −$1.2M | $82,643 | — | — |
| Q3 2018 | 2018-09-30 | −$1.6M | −$328,499 | — | — |
| Q2 2018 | 2018-06-30 | −$1.2M | $4.4M | — | — |
| Q1 2018 | 2018-03-31 | −$1.6M | $2.5M | — | — |
| Q4 2017 | 2017-12-31 | −$1.3M | $1.8M | — | — |
| Q3 2017 | 2017-09-30 | −$1.2M | $3.1M | — | — |
| Q2 2017 | 2017-06-30 | −$5.6M | −$429,725 | — | — |
| Q1 2017 | 2017-03-31 | −$4.0M | −$717,818 | — | — |
| Q4 2016 | 2016-12-31 | −$3.1M | −$403,197 | — | — |
| Q3 2016 | 2016-09-30 | −$4.3M | −$1.1M | — | — |
| Q2 2016 · Jun 30 | 2016-06-30 | −$5.2M | −$1.3M | — | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$3.3M | −$526,684 | — | — |
| Q2 2016 · Oct 31 | 2015-10-31 | −$2.7M | −$159,115 | — | — |
| Q2 2016 · Sep 30 | 2015-09-30 | −$3.2M | $79,375 | — | — |
| Q1 2016 · Jul 31 | 2015-07-31 | −$3.9M | −$947,215 | — | — |
| Q1 2016 · Jun 30 | 2015-06-30 | −$2.8M | −$813,689 | — | — |
| Q1 2016 · Mar 31 | 2015-03-31 | −$2.5M | $437,161 | — | — |
| Q3 2015 | 2015-01-31 | −$3.2M | −$515,702 | — | — |
| Q2 2015 | 2014-10-31 | −$2.9M | −$899,222 | — | — |
| Q1 2015 | 2014-07-31 | −$2.0M | −$419,235 | — | — |
| Q4 2014 | 2014-04-30 | −$3.0M | −$1.5M | — | — |
| Q3 2014 | 2014-01-31 | −$2.7M | −$2.0M | — | −6485.50% |
| Q2 2014 | 2013-10-31 | −$2.0M | −$884,289 | — | −3613.96% |
| Q1 2014 | 2013-07-31 | −$1.6M | $62,455 | — | −942.76% |
| Q4 2013 | 2013-04-30 | −$1.4M | −$15,536 | — | −794.57% |
| Q3 2013 | 2013-01-31 | −$741,223 | $1.5M | — | −333.30% |
| Q2 2013 | 2012-10-31 | −$1.1M | $1.4M | — | −219.27% |
| Q1 2013 | 2012-07-31 | −$1.6M | $428,208 | — | −597.44% |
| Q4 2012 | 2012-04-30 | −$1.4M | $376,740 | — | −1494.64% |
| Q3 2012 | 2012-01-31 | −$2.3M | $312,533 | — | −1535.46% |
| Q2 2012 | 2011-10-31 | −$2.5M | −$712,245 | — | −2667.66% |
| Q1 2012 | 2011-07-31 | −$2.1M | $648,516 | — | −8257.17% |
| Q4 2011 | 2011-04-30 | −$1.8M | — | — | — |
| Q3 2011 | 2011-01-31 | −$2.6M | — | — | −9737.26% |
| Q2 2011 | 2010-10-31 | −$1.8M | — | — | −6732.56% |
| Q1 2011 | 2010-07-31 | −$2.7M | — | — | — |
Tenax Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$12.1M to −$11.4M, a net increase of $754,160. Tenax Therapeutics's latest reported quarter, Q2 2023, generated −$924,568 in free cash flow, an increase of $2.5M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tenax Therapeutics filings at SEC.gov ↗